or Try an Advanced Search...

    Cognitive Disorders Stocks List

    Symbol Grade Name % Change
    OMER C Omeros Corporation 0.78
    ITCI C Intra-Cellular Therapies Inc. 0.77
    ANVS D Annovis Bio, Inc. -12.93
    CGTX D Cognition Therapeutics, Inc. -2.75
    ARCT F Arcturus Therapeutics Ltd. 2.09
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Alzheimer's Disease Disorders Medicine Parkinson's Disease Psychiatric Diagnosis Aging Associated Diseases Cognitive Impairment Dementia Early Stage Alzheimer's Disease Learning Disabilities Neurodegeneration Schizophrenia Addiction Adhd Amphetamine Amyloid Arthroscopy Autism Autism Spectrum Disorder

    Related ETFs - A few ETFs which own one or more of the above listed Cognitive Disorders stocks.

    Symbol Grade Name Weight
    PSIL F AdvisorShares Psychedelics ETF 4.65
    XPH D SPDR S&P Pharmaceuticals ETF 4.14
    IBRN D iShares Neuroscience and Healthcare ETF 4.07
    ARKG F ARK Genomic Revolution Multi-Sector ETF 3.7
    FBT B First Trust Amex Biotech Index Fund 3.4
    View all Cognitive Disorders ETFs...
    Compare ETFs
    Compare PSIL to FBT Compare PSIL to XPH Compare XPH to IBRN

        Cognitive Disorders Stocks Recent News

        Date Stock Title
        Jul 3 ANVS Annovis stock swells after Phase III Parkinson’s subgroup success
        Jul 3 ANVS Annovis Bio shares dip on phase III Parkinson's trial data
        Jul 3 ANVS Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
        Jul 3 ANVS Tesla, Paramount Global, Annovis Bio, Eli Lilly, Amazon: Why These 5 Stocks Are On Investors' Radars Today
        Jul 2 ANVS Annovis doubles as lead drug improves Parkinson’s
        Jul 2 ANVS Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
        Jul 2 CGTX Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
        Jul 1 ARCT Arcturus to file IND for phase 2 study for cystic fibrosis candidate
        Jul 1 ARCT Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
        Jun 30 ANVS Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
        Jun 28 ANVS Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
        Jun 27 ANVS CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
        Jun 27 ANVS Annovis Bio files patent for new manufacturing process of buntanetap
        Jun 27 ANVS Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Alzheimer's Disease Disorders Medicine Parkinson's Disease Psychiatric Diagnosis Aging Associated Diseases Cognitive Impairment Dementia Early Stage Alzheimer's Disease Learning Disabilities Neurodegeneration Schizophrenia Addiction Adhd Amphetamine Amyloid Arthroscopy Autism Autism Spectrum Disorder
        Cognitive Disorders

        Cognitive Disorders are a group of mental health conditions that affect a person's ability to think, remember, and learn. These disorders can range from mild to severe and can include conditions such as dementia, Alzheimer's disease, and traumatic brain injury. Symptoms of cognitive disorders can include difficulty with memory, concentration, problem-solving, and decision-making. Treatment for cognitive disorders typically involves a combination of medication, therapy, and lifestyle changes.

        Browse All Tags